Immunoglobulin E specific for timothy grass allergens (Timothy grass-specific IgE)

Immunoglobulin E (IgE) specific for timothy grass allergens is a specialized antibody class that mediates Type I hypersensitivity reactions to Phleum pratense pollen. These antibodies are produced by B cells following sensitization to major grass allergens such as Phl p 1 and Phl p 5 (Valenta et al., 2019). Upon re-exposure, the allergens cross-link IgE molecules bound to FcεRI receptors on mast cells and basophils, triggering the release of inflammatory mediators like histamine, which cause symptoms of allergic rhinitis and asthma (Galli & Tsai, 2012). Therapeutic strategies focus on either neutralizing circulating IgE using monoclonal antibodies like Omalizumab or inducing immune tolerance through allergen-specific immunotherapy (AIT). AIT aims to shift the immune response from a Th2-driven IgE production toward a regulatory T-cell response and the production of protective IgG4 antibodies (Durham & Shamji, 2023). Monitoring the levels of these specific IgE antibodies is essential for clinical diagnosis and for evaluating the efficacy of desensitization protocols.

Other names

Phleum pratense-specific IgETimothy grass sIgEAnti-Phl p IgEGrass pollen-specific IgE

Omalizumab acts by binding to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (National Institutes of Health, 2023). Allergen-specific immunotherapy (AIT) involves the repeated administration of timothy grass allergens to induce peripheral T-cell tolerance and promote the production of blocking IgG4 antibodies that compete with IgE for allergen binding (Bousquet et al., 2020).